Cargando…
What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study
Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for e...
Autores principales: | Taj, Hafiza Munazza, Talib, Maryam, Siddiqa, Sania, Sarfraz, Azza, Sarfraz, Zouina, Robles-Velasco, Karla, Cherrez-Ojeda, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690388/ https://www.ncbi.nlm.nih.gov/pubmed/36360540 http://dx.doi.org/10.3390/healthcare10112199 |
Ejemplares similares
-
Indicators of Climate Change, Geospatial and Analytical Mapping of Trends in India, Pakistan and Bangladesh: An Observational Study
por: Falak, Faiqa, et al.
Publicado: (2022) -
Ileal Bile Acid Transporter Blockers for Cholestatic Liver Disease in Pediatric Patients with Alagille Syndrome: A Systematic Review and Meta-Analysis
por: Muntaha, Hafiza Sidra tul, et al.
Publicado: (2022) -
Addressing the Endometriosis Knowledge Gap for Improved Clinical Care—A Cross-Sectional Pre- and Post-Educational-Intervention Study among Pakistani Women
por: Saad, Muhammad, et al.
Publicado: (2023) -
Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
por: Rashad, Areeba, et al.
Publicado: (2022) -
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Ul Amin, Noor, et al.
Publicado: (2022)